The Canadian media outlet The Globe and Mail reported on May 12 local time that it had learned from the National Research Council of Canada that Canadian researchers are working with China to develop a new crown vaccine and will conduct related clinical trials in Canada.
The vaccine, known as Ad5-nCoV, was developed by a Chinese company in collaboration with the Canadian military, and is one of many new crown vaccines developed around the world.
China and Canada have reached an agreement to produce this vaccine in Canada for clinical trials and emergency use, and to continue development.
Roman Szumski, deputy director for life sciences research at the National Research Council of Canada, said the vaccine has already undergone Phase I and Phase II clinical trials in China, and continued clinical trials in Canada could provide further insight into the safety and effectiveness of the vaccine.
If the clinical trial goes well, the vaccine will be submitted to Health Canada for approval and authorization for emergency use, possibly as early as this fall.
The Chinese and Canadian companies that are reportedly collaborating on the development of the new crown vaccine are Conciano Biologicals, Inc. in Tianjin, China, and the Canadian Academy of Military Medical Sciences Biotechnology Institute. It is understood that the cooperating China and Canada have previously worked together to develop a successful Ebola virus vaccine.
This recombinant vaccine uses a variety of viral strains that have been genetically recombined to contain the prickly protein of the new crown virus. Once used by the human body, the body’s immune system can recognize and destroy the coronavirus.
Lakshmi Krishnan, Secretary General of the Canadian National Research Council’s Centre for Therapeutic Research in Human Health, explained that the new coronavirus vaccine being developed takes a cell line called HEK293, which is the result of research in Canada over a decade ago, and uses it as a “living cell factory” to produce any vaccine product.
Source: CCTV News Client.[wl_faceted_search]